Huerta, Miguel Á.García, Miguel M.García Parra, BeliuSerrano Afonso, AncorPaniagua, Nancy2023-09-212023-09-212023-08-201422-0067https://hdl.handle.net/2445/202075The pharmacological treatment of postherpetic neuralgia (PHN) is unsatisfactory, and there is a clinical need for new approaches. Several drugs under advanced clinical development are addressed in this review. A systematic literature search was conducted in three electronic databases (Medline, Web of Science, Scopus) and in the ClinicalTrials.gov register from 1 January 2016 to 1 June 2023 to identify Phase II, III and IV clinical trials evaluating drugs for the treatment of PHN. A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets: Angiotensin Type 2 Receptor (AT2R) antagonism (olodanrigan), Voltage-Gated Calcium Channel (VGCC) a2d subunit inhibition (crisugabalin, mirogabalin and prega-balin), Voltage-Gated Sodium Channel (VGSC) blockade (funapide and lidocaine), Cyclooxygenase-1 (COX-1) inhibition (TRK-700), Adaptor-Associated Kinase 1 (AAK1) inhibition (LX9211), Lanthionine Synthetase C-Like Protein (LANCL) activation (LAT8881), N-Methyl-D-Aspartate (NMDA) receptor antagonism (esketamine), mu opioid receptor agonism (tramadol, oxycodone and hydromorphone) and Nerve Growth Factor (NGF) inhibition (fulranumab). In brief, there are several drugs in ad-vanced clinical development for treating PHN with some of them reporting promising results. AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN.19 p.application/pdfengcc by (c) Huerta, Miguel Á. et al., 2023http://creativecommons.org/licenses/by/3.0/es/Herpes zòsterNeuropaties perifèriquesFarmacologiaShingles (Disease)Peripheral neuropathiesPharmacologyinfo:eu-repo/semantics/article2023-09-18info:eu-repo/semantics/openAccess37629168